

## Entry into a Material Definitive Agreement

**MINNEAPOLIS, United States and BRISBANE, Australia 24 April 2026 (AEST): Anteris Technologies Global Corp. (Anteris or the Company)** (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, filed the attached Form 8-K with the U.S. Securities and Exchange Commission (the **SEC**) on 23 April 2026 US Eastern Time (24 April 2026 AEST).

**ENDS**

### About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR<sup>®</sup> THV, was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR<sup>®</sup> THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR<sup>®</sup> THV is made using a single piece of molded ADAPT<sup>®</sup> tissue, Anteris' patented anti-calcification tissue technology. ADAPT<sup>®</sup> tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR<sup>®</sup> THV System is comprised of the DurAVR<sup>®</sup> valve, the ADAPT<sup>®</sup> tissue, and the balloon-expandable ComASUR<sup>®</sup> Delivery System. The safety and efficacy of the DurAVR<sup>®</sup> THV are being evaluated in the PARADIGM Trial (NCT07194265), with the first patients enrolled and implanted with the DurAVR<sup>®</sup> THV in Denmark during the fourth quarter of 2025.

### Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the anticipated closing date for the Offering and Private Placement and the anticipated use of the net proceeds of the Offering and the Private Placement. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in the Registration Statement and the final prospectus supplement and accompanying prospectus. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to



update any of these forward-looking statements to conform these statements to actual results or revised expectations.

### Authorisation and Additional information

This announcement was authorised for release on the ASX by the Chief Executive Officer.

### For more information:

#### Investor Relations

investors@anteristech.com

Debbie Ormsby

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

Website

[www.anteristech.com](http://www.anteristech.com)

X

@AnterisTech

LinkedIn

<https://www.linkedin.com/company/anteristech>

#### Investor Relations (US)

mchatterjee@bplifescience.com

Malini Chatterjee, Ph.D.

Blueprint Life Science Group

+1 917 330 4269



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d)  
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2026

**Anteris Technologies Global Corp.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

001-42437  
(Commission File Number)

99-1407174  
(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302  
9 Sherwood Road  
Toowong, QLD  
Australia  
(Address of Principal Executive Offices)

4066  
(Zip Code)

Registrant's telephone number, including area code: +61 7 3152 3200

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	AVR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01. Entry into a Material Definitive Agreement.**

*Lease Agreement*

On April 23, 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), entered into a lease agreement (the “Lease”) with Northcross West Industrial Owner, LLC (“Northcross”) for approximately 181,436 square feet of space in an office and warehouse facility located in Brooklyn Park, Minnesota.

The Lease has an initial term commencing September 1, 2026 and expiring August 31, 2037 and may be extended for two periods of 84 months each at market rent, subject to other terms and conditions set forth therein. Under the Lease, the Company is required to pay monthly minimum rent initially of \$152,708.63, subject to contractual rent abatements, annual escalations and other adjustments as provided in the Lease, plus real estate taxes, operating expenses and other charges. Rent for the first three months of the Lease will be completely abated so long as the Company is not in default of the lease and rent for the succeeding nine months will be partially abated.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026.

---

For personal use only

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Anteris Technologies Global Corp.**

Date: April 23, 2026

By: /s/ Wayne Paterson

Name: Wayne Paterson

Title: Vice Chairman and Chief Executive Officer

---

For personal use only